Senthil Sundaram
Nessuna posizione attualmente
Profilo
Senthil Sundaram held several positions in the pharmaceutical industry, including Chief Executive Officer & Director at Terns Pharmaceuticals, Inc., Vice President & Head-Business Development at Intercept Pharmaceuticals, Inc., and CFO & Principal Accounting Officer at Nightstar Therapeutics Ltd.
He also served as an Independent Director at Sio Gene Therapies, Inc. and Social Capital Suvretta Holdings Corp.
I.
Sundaram received his undergraduate degree from Brown University.
Precedenti posizioni note di Senthil Sundaram
| Società | Posizione | Fine |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Amministratore Delegato | 03/08/2023 |
| SIO GENE THERAPIES INC. | Direttore/Membro del Consiglio | 05/04/2023 |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 07/06/2019 |
| NIGHTSTAR THERAPEUTICS PLC | Direttore Finanziario/CFO | 07/06/2019 |
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2017 |
Formazione di Senthil Sundaram
| Brown University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Social Capital Suvretta Holdings Corp. I
 Social Capital Suvretta Holdings Corp. I Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. I is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on the search for target business operating in the biotechnology industry and within the neurology subsector. The company was founded by Chamath Palihapitiya and Kishen C. Mehta on February 25, 2021 and is headquartered in Henderson, NV. | Finance |
- Borsa valori
- Insiders
- Senthil Sundaram